You are here




Coverage of the latest news and updates from the field of stem cells.

October 25, 2017

Researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels to proliferate.

October 23, 2017

Killing cancer cells indirectly by powering up fat cells in the bone marrow could help acute myeloid leukemia patients, according to a new study from McMaster University.

October 23, 2017

Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the United States in 2017, according to the Centers for Disease Control and Prevention.

October 20, 2017

For the first time, researchers have created expanded potential stem cells (EPSCs) in mice that, they report, have a greater potential for development than current stem cell lines.

October 16, 2017

A team of researchers has tracked down the cellular origin of cutaneous melanoma, the deadliest form of skin cancer. They observed that these very aggressive tumors arise from mature, pigment-producing cells called melanocytes.

October 16, 2017

Li Gan, Ph.D., wants to find treatments to help patients with Alzheimer’s disease. Like most researchers, she’s hit a few major roadblocks.

October 11, 2017

A new study carried out by the University of Oxford has used flat worms to look at the role of migrating stem cells in cancer.

October 9, 2017

New research has shed light on the complex process that occurs in the development of human sperm stem cells. This study is reportedly the first to characterize the changes human sperm stem cells undergo as they mature.

October 9, 2017

In a recent clinical trial, a gene therapy to treat cerebral adrenoleukodystrophy (CALD) — a neurodegenerative disease that typically claims young boys' lives within 10 years of diagnosis — effectively stabilized the disease's progression in 88 percent of patients, researchers from the Dana-Farbe

October 6, 2017

A new clinical trial, known as the BATTLE study, will focus on the maintenance treatment of patients with intermediate and high-risk acute myeloid leukemia (AML) who have achieved a complete response (CR) following induction and consolidation therapy.